Diagnosis and management of pancreatic cancer

American Family Physician

Volumn 89, Issue 8, 2014, Pages 626-632

  De La Cruz, Maria Syl D ^a   Young, Alisa P ^b   Ruffin IV, Mack T ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 19-9 ANTIGEN; CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GASTROJEJUNOSTOMY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RISK FACTOR; SMOKING; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; TUMOR VOLUME;

CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSIS, DIFFERENTIAL; ENDOSONOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 84898858497     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. American Cancer Society. Cancer facts & figures 2011. http://www. cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011. Accessed March 16, 2012.
3. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology. Pancreatic adenocarcinoma. Version 1.2014.http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf [subscription required]. Accessed February 25, 2014.
4. Lochan R, Daly AK, Reeves HL, Charnley RM. Genetic susceptibility in pancreatic ductal adenocarcinoma. Br J Surg. 2008;95(1):22-32.
5. Ojajärvi IA, Partanen TJ, Ahlbom A, et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med. 2000;57(5): 316-324.
6. Brand RE, Lerch MM, Rubinstein WS, et al.; Participants of the Fourth International Symposium of Inherited Diseases of the Pancreas. Advances in counseling and surveillance of patients at risk for pancreatic cancer. Gut. 2007;56(10):1460-1469.
7. Screening for pancreatic cancer: recommendation statement. February 2004. http://www.uspreventiveservicestaskforce.org/3rduspstf/ pancreatic/pancrers.htm. Accessed February 10, 2014.
8. Stoita A, Penman ID, Williams DB. Review of screening for pancreatic cancer in high risk individuals. World J Gastroenterol. 2011;17(19):2365-2371.
9. Krech RL, Walsh D. Symptoms of pancreatic cancer. J Pain Symptom Manage. 1991;6(6):360-367.
10. Di Magno EP. Cancer of the pancreas and biliary tract. In: Winawer SJ, ed. Management of Gastrointestinal Diseases. New York, NY: Gower Medical Publishing; 1992:28.9
11. American Gastroenterological Association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 1999;117 (6):1463-1484.
12. Girelli CM, Reguzzoni G, Limido E, Savastano A, Rocca F. Pancreatic carcinoma: differences between patients with or without diabetes mellitus. Recenti Prog Med. 1995;86(4):143-146.
13. Palpation and percussion of the abdomen. In: McGee SR. Evidence- Based Physical Diagnosis. Philadelphia, Pa.: Saunders; 2001:1-4.
14. Klauss M, Schöbinger M, Wolf I, et al. Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol. 2009;15(46):5827-5832.
15. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008;6(12):1301-1308.
16. Oh HC, Kim MH, Hwang CY, et al. Cystic lesions of the pancreas: challenging issues in clinical practice. Am J Gastroenterol. 2008;103(1):229-239.
17. Safi F, Roscher R, Bittner R, Schenkluhn B, Dopfer HP, Beger HG. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas. 1987;2(4):398-403.
18. Edge SB, American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
19. National Cancer Institute. SEER stat fact sheets: pancreas cancer. http:// seer.cancer.gov/statfacts/html/pancreas.html. Accessed March 16, 2012.
20. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004; 363(9414):1049-1057.
21. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727-1733.
22. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg. 1987; 206(3):358-365.
23. Ho V, Heslin MJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg. 2003;237(4):509-514.
24. Imperato PJ, Nenner RP, Starr HA, Will TO, Rosenberg CR, Dearie MB. The effects of regionalization on clinical outcomes for a high risk surgical procedure: a study of the Whipple procedure in New York State. Am J Med Qual. 1996;11(4):193-197.
25. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg. 1995;222(5):638-645.
26. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg. 1998;228(3):429-438.
27. Diener MK, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev. 2011;(5):CD006053.
28. Neoptolemos JP, Stocken DD, Friess H, et al.; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer [published correction appears in N Engl J Med. 2004;351(7):726]. N Engl J Med. 2004; 350(12):1200-1210.
29. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567-579.
30. Gourgou-Bourgade S, Bascoul-Molevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ ACCORD 11 randomized trial. J Clin Oncol. 2013;31(1):23-29.
31. Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer-part I: neoadjuvant treatment. Semin Radiat Oncol. 2005;15(4):226-234.
32. Conroy T, Desseigne F, Ychou M, et al.; Groupe Tumeurs Digestive of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
33. Quiros RM, Brown KM, Hoffman JP. Neoadjuvant therapy in pancreatic cancer. Cancer Invest. 2007;25(4):267-273.
34. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115(3): 665-672.
35. Conroy T, Desseigne F, Ychou M, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol. 2010;28 (15 suppl; abstr 4010).
36. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Adult cancer pain. http://www.nccn.org/ professionals/physician_gls/pdf/pain.pdf [subscription required]. Accessed February 25, 2014.
37. House MG, Choti MA. Palliative therapy for pancreatic/biliary cancer. Surg Clin North Am. 2005;85(2):359-371.
38. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev. 2006;(2):CD004200.
39. Jeurnink SM, Steyerberg EW, Hof G, van Eijck CH, Kuipers EJ, Siersema PD. Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients. J Surg Oncol. 2007;96(5):389-396.
40. Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007;7:18.
41. Sikkens EC, Cahen DL, Kuipers EJ, Bruno MJ. Pancreatic enzyme replacement therapy in chronic pancreatitis. Best Pract Res Clin Gastroenterol. 2010;24(3):337-347.
42. Lee AY, Levine MN, Baker RI, et al.; Randomized Comparison of Low- Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
43. Holland JC, Alici Y. Management of distress in cancer patients. J Support Oncol. 2010;8(1):4-12.
44. Tempero MA, Arnoletti JP, Behrman S, et al.; NCCN Pancreatic Adenocarcinoma Panel Members. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010;8(9):972-1017.
45. Sheffield KM, Crowell KT, Lin YL, Djukom C, Goodwin JS, Riall TS. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol. 2012;19(5):1670-1677.